MENU
ALEC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Alector (ALEC) Earnings Date & Reports

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

ALEC is expected to report earnings to fall 120.08% to -22 cents per share on March 02

Alector ALEC Stock Earnings Reports
Q4'26
Est.
$-0.22
Q3'26
Beat
by $1.34
Q2'26
Beat
by $0.02
Q1'26
Beat
by $0.07
Q4'25
Beat
by $0.05
The last earnings report on November 05 showed earnings per share of $1.11, beating the estimate of -23 cents. With 298.41K shares outstanding, the current market capitalization sits at 255.69M.
A.I.Advisor
Nov 06, 2026

Alector, Inc. (ALEC) Third Quarter 2026 Earnings Recap: A Surprising Swing to Profit Shifts the Story

Key Takeaways

  • Alector, Inc. (ALEC) reported third quarter 2026 results, for the period ended September 30, 2026, on November 5, 2026.
  • Collaboration revenue jumped to $162.9 million, up from $3.3 million a year earlier, driven by a one-time recognition of deferred revenue after GSK terminated its collaboration.
  • Net income swung to $124.6 million, or $1.11 per share, versus a net loss of $34.7 million, or $0.34 per share, in the prior-year quarter.
  • Research and development (R&D) expenses were $30.0 million, while general and administrative (G&A) expenses were $9.0 million.
  • Cash, cash equivalents, and investments totaled $138.7 million at quarter-end, excluding a $100 million Genentech upfront payment and roughly $75 million in gross proceeds from an October stock offering.
  • Management expects its cash position to fund operations into the second half of 2029.
  • For more detail on Alector's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
  • Explore Trending AI Robots for AI-driven trading signals and market insights.

Earnings Context and Why It Matters

Alector is a clinical-stage biotechnology company focused on immuno-neurology, developing therapies to counteract neurodegeneration. Its third quarter 2026 report arrives at a pivotal moment: the company recently struck a global licensing deal with Genentech, a member of the Roche Group, for its AL050 program, and simultaneously absorbed the termination of its collaboration with GSK. For investors, the quarter's headline figures are less about recurring operations and more about the company's transformed balance sheet, extended cash runway, and newly streamlined pipeline. Understanding how much of the reported profit is one-time in nature — versus a sustainable shift — is central to interpreting the results.

Reported Results

Alector reported collaboration revenue of $162.9 million for the third quarter of 2026, compared with $3.3 million in the same period of 2025. The sharp increase primarily reflected the recognition of remaining deferred revenue under its Collaboration and License Agreement with GSK, following GSK's July 2026 termination notice and the extinguishment of Alector's remaining performance obligations.

The company posted net income of $124.6 million, or $1.11 per share, versus a net loss of $34.7 million, or $0.34 per share, a year earlier. This dramatically exceeded the consensus estimate of a loss of $0.23 per share on revenue of roughly $2.38 million, though the outperformance was driven by non-recurring accounting items rather than operating strength.

On the expense side, R&D costs were $30.0 million, up modestly from $29.4 million, reflecting option and license fees partially offset by lower latozinemab and nivisnebart program costs and personnel reductions. G&A expenses declined to $9.0 million from $11.5 million. Alector ended the quarter with $138.7 million in cash, cash equivalents, and investments, a figure that excludes the $100 million Genentech upfront payment and the net proceeds of its October 2026 underwritten offering of 36.6 million shares priced at $2.05 per share.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for earnings-focused and technical investors alike. Explore the AI Screener to refine your own watchlist today.

Market Reaction and Investor Sentiment

Alector's stock entered the report following a dramatic October rally, when shares surged on news that Roche's Genentech would license the AL050 program in a deal worth up to roughly $1.27 billion including the upfront payment and milestone potential. That run-up set a high bar heading into earnings. On the release day, shares pulled back in regular trading before recovering modestly in after-hours activity, reflecting profit-taking after the prior surge as well as investor recognition that the quarter's profit was largely a one-time, non-cash accounting result. Sentiment remains focused on the durability of the company's cash runway and the clinical path of its wholly owned pipeline rather than the headline earnings beat.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will likely shift their attention from the one-time revenue recognition toward Alector's long-term pipeline economics. The Genentech agreement provides $100 million in near-term capital plus up to an additional $1.17 billion in development, regulatory, and commercial milestones, along with tiered royalties — a substantial de-risking event for the AL050 program.

Key catalysts include progress on AL137, the company's lead anti-amyloid beta antibody, as well as the AL164 tau program and AL062 alpha-synuclein program, which utilize small interfering RNA (siRNA) technology. Alector has targeted first-in-human subcutaneous dosing for one program in Australia no later than April 2027.

Investors should also monitor spending discipline, as reduced personnel and wind-down costs have helped narrow operating expenses. With management projecting a cash runway into the second half of 2029, the company's ability to advance its pipeline without additional near-term dilution will be a central theme in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders

Industry Biotechnology

Industry
Biotechnology
Address
131 Oyster Point Boulevard
Phone
+1 415 231-5660
Employees
103
Web
https://www.alector.com